ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,543.96
-0.16%
S&P 500
5,360.79
0.26%
Dow Jones
38,868.04
0.18%
US Dollar vs Yen
157.035
0.13%
Brent Oil
81.76
3.04%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Quoin Pharmaceuticals Ltd (QNRX)

  7. Quoin Pharmaceuticals Ltd (QNRX) ニュース

QNRX

Quoin Pharmaceuticals (QNRX)

Quoin Pharmaceuticals Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:QNRX
日付受信時刻ニュースソース見出しコード企業名
2024/05/1105 : 10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/05/0921 : 30GlobeNewswire Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial ResultsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/05/0905 : 00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/05/0305 : 10GlobeNewswire Inc.Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/1405 : 05GlobeNewswire Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/1320 : 03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/0906 : 06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/0906 : 04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/0906 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/0806 : 05GlobeNewswire Inc.Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ETNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/0707 : 07Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/0706 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/0522 : 00GlobeNewswire Inc.Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public OfferingNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/0507 : 27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/03/0422 : 00GlobeNewswire Inc.Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical StudiesNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/02/2720 : 01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/02/1514 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/02/1410 : 11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/02/1406 : 50Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/02/1406 : 30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/02/1307 : 12Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/02/0822 : 00GlobeNewswire Inc.Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination ProductNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2024/01/3106 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2023/12/1907 : 30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2023/12/1907 : 29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2023/12/1322 : 30GlobeNewswire Inc.Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton SyndromeNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2023/11/1007 : 15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2023/11/1007 : 11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
2023/11/1007 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
2023/11/0907 : 46GlobeNewswire Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial ResultsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:QNRX

最近閲覧した銘柄

NYSE
MRK
Merck
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLV
Health Care Select Sector
CCOM
US100
US Tech 100
NASDAQ
NVDA
NVIDIA
CCOM
US30
US 30
USOTC
BASFY
BASF (QX)
NASDAQ
AMZN
Amazon.com
NYSE
NKE
Nike
FX
USDEUR
US Dollar vs Euro
FX
USDGBP
US Dollar vs Sterling
NYSE
BAC
Bank of America
CCOM
US500
US 500
NASDAQ
AAPL
Apple
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有